The new method, still being tested with mouse models, could help clinicians see blood vessels with improved clarity. 

The FDA has been busy, sharing recommendations and clearing solutions that could have a significant impact on cardiovascular care throughout the United States. 

Data from the FOURIER trial helped clinicians learn more about this popular PCSK9 inhibitor.

Mortality rates can be especially high for ischemic HF patients presenting with FMR and LVSD, but PCI may offer some relief. 

The three-month mortality rate was 2.4% after thrombolysis and 18.7% after surgery.

Nearly 19,000 patients with newly diagnosed atrial fibrillation were included in the team's analysis. 

The new meta-analysis, published in the American Journal of Cardiology, includes data from 16 different studies. 

New trainees may not necessarily lead to a higher risk of medical errors during PCI.